published meta-analysis   sensitivity analysis   studies

sotrovimab (Xevudy; VIR-7831) in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] 1.02[0.48; 2.17]ACTIV-3/ TICO (sotrovimab), 202110%367NAnot evaluable deaths (time to event analysis only)detailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17] 1.02[0.48; 2.17]ACTIV-3/ TICO (sotrovimab), 202110%367NAnot evaluable recoverydetailed resultsACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37] 1.12[0.91; 1.37]ACTIV-3/ TICO (sotrovimab), 202110%360NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-04-19 02:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 880 - roots T: 290